20 results on '"Koelle, David M."'
Search Results
2. SJS/TEN 2019: From science to translation
- Author
-
Chang, Wan-Chun, Abe, Riichiro, Anderson, Paul, Anderson, Wanpen, Ardern-Jones, Michael R., Beachkofsky, Thomas M., Bellón, Teresa, Biala, Agnieszka K., Bouchard, Charles, Cavalleri, Gianpiero L., Chapman, Nicole, Chodosh, James, Choi, Hyon K., Cibotti, Ricardo R., Divito, Sherrie J., Dewar, Karen, Dehaeck, Ulrike, Etminan, Mahyar, Forbes, Diane, Fuchs, Esther, Goldman, Jennifer L., Holmes, James H., IV, Hope, Elyse A., Hung, Shuen-Iu, Hsieh, Chia-Ling, Iovieno, Alfonso, Jagdeo, Julienne, Kim, Mee Kum, Koelle, David M., Lacouture, Mario E., Le Pallec, Sophie, Lehloenya, Rannakoe J., Lim, Robyn, Lowe, Angie, McCawley, Jean, McCawley, Julie, Micheletti, Robert G., Mockenhaupt, Maja, Niemeyer, Katie, Norcross, Michael A., Oboh, Douglas, Olteanu, Cristina, Pasieka, Helena B., Peter, Jonathan, Pirmohamed, Munir, Rieder, Michael, Saeed, Hajirah N., Shear, Neil H., Shieh, Christine, Straus, Sabine, Sukasem, Chonlaphat, Sung, Cynthia, Trubiano, Jason A., Tsou, Sheng-Ying, Ueta, Mayumi, Volpi, Simona, Wan, Chen, Wang, Hongsheng, Wang, Zhao-Qing, Weintraub, Jessica, Whale, Cindy, Wheatley, Lisa M., Whyte-Croasdaile, Sonia, Williams, Kristina B., Wright, Galen, Yeung, Sonia N., Zhou, Li, Chung, Wen-Hung, Phillips, Elizabeth J., and Carleton, Bruce C.
- Published
- 2020
- Full Text
- View/download PDF
3. Spike-specific T cells are enriched in breastmilk following SARS-CoV-2 mRNA vaccination.
- Author
-
Armistead, Blair, Jiang, Yonghou, Carlson, Marc, Ford, Emily S., Jani, Saumya, Houck, John, Wu, Xia, Jing, Lichen, Pecor, Tiffany, Kachikis, Alisa, Yeung, Winnie, Nguyen, Tina, Coig, Rene, Minkah, Nana, Larsen, Sasha E., Coler, Rhea N., Koelle, David M., and Harrington, Whitney E.
- Published
- 2023
- Full Text
- View/download PDF
4. Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays
- Author
-
Chen, Xianfeng, Kask, Angela Shaulov, Crichton, Michael L., McNeilly, Celia, Yukiko, Sally, Dong, Lichun, Marshak, Joshua O., Jarrahian, Courtney, Fernando, Germain J.P., Chen, Dexiang, Koelle, David M., and Kendall, Mark A.F.
- Published
- 2010
- Full Text
- View/download PDF
5. HSV-1 employs UL56 to antagonize expression and function of cGAMP channels.
- Author
-
Blest, Henry T.W., Redmond, Alexander, Avissar, Jed, Barker, Jake, Bridgeman, Anne, Fowler, Gerissa, Chauveau, Lise, Hertzog, Jonny, Vendrell, Iolanda, Fischer, Roman, Iversen, Marie B., Jing, Lichen, Koelle, David M., Paludan, Søren R., Kessler, Benedikt M., Crump, Colin M., and Rehwinkel, Jan
- Abstract
DNA sensing is important for antiviral immunity. The DNA sensor cGAS synthesizes 2′3′-cyclic GMP-AMP (cGAMP), a second messenger that activates STING, which induces innate immunity. cGAMP not only activates STING in the cell where it is produced but cGAMP also transfers to other cells. Transporters, channels, and pores (including SLC19A1, SLC46A2, P2X7, ABCC1, and volume-regulated anion channels (VRACs)) release cGAMP into the extracellular space and/or import cGAMP. We report that infection with multiple human viruses depletes some of these cGAMP conduits. This includes herpes simplex virus 1 (HSV-1) that targets SLC46A2, P2X7, and the VRAC subunits LRRC8A and LRRC8C for degradation. The HSV-1 protein UL56 is necessary and sufficient for these effects that are mediated at least partially by proteasomal turnover. UL56 thereby inhibits cGAMP uptake via VRAC, SLC46A2, and P2X7. Taken together, HSV-1 antagonizes intercellular cGAMP transfer. We propose that this limits innate immunity by reducing cell-to-cell communication via the immunotransmitter cGAMP. [Display omitted] • Viruses including HSV-1, VACV, and ZIKV modulate levels of cGAMP conduits • HSV-1 targets SLC46A2, P2X7, and the VRAC subunits LRRC8A and LRRC8C • UL56 is necessary and sufficient for degradation of these cGAMP conduits • UL56 thereby limits STING-dependent IFN responses to extracellular cGAMP Blest et al. show that multiple viruses antagonize transmembrane proteins mediating cGAMP import and export. For example, HSV-1 targets VRAC, SLC46A2, and P2X7. The HSV-1 protein UL56 is necessary and sufficient for degradation of these cGAMP conduits. UL56 thereby curtails the capacity of cells to respond to extracellular cGAMP. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
- Author
-
Limaye, Ajit P., Corey, Lawrence, Koelle, David M., Davis, Connie L., and Boeckh, Michael
- Published
- 2000
7. Corrigendum to ‘SJS/TEN 2019: From science to translation’ [J. Dermatol. Sci. 98/1 (2020) 2–12]
- Author
-
Chang, Wan-Chun, Abe, Riichiro, Anderson, Paul, Anderson, Wanpen, Ardern-Jones, Michael R., Beachkofsky, Thomas M., Bellón, Teresa, Biala, Agnieszka K., Bouchard, Charles, Cavalleri, Gianpiero L., Chapman, Nicole, Chodosh, James, Choi, Hyon K., Cibotti, Ricardo R., Divito, Sherrie J., Dewar, Karen, Dehaeck, Ulrike, Etminan, Mahyar, Forbes, Diane, Fuchs, Esther, Goldman, Jennifer L., Holmes, James H., IV, Hope, Elyse A., Hung, Shuen-Iu, Hsieh, Chia-Ling, Iovieno, Alfonso, Jagdeo, Julienne, Kim, Mee Kum, Koelle, David M., Lacouture, Mario E., Le Pallec, Sophie, Lehloenya, Rannakoe J., Lim, Robyn, Lowe, Angie, McCawley, Jean, McCawley, Julie, Micheletti, Robert G., Mockenhaupt, Maja, Niemeyer, Katie, Norcross, Michael A., Oboh, Douglas, Olteanu, Cristina, Pasieka, Helena B., Peter, Jonathan, Pirmohamed, Munir, Rieder, Michael, Saeed, Hajirah N., Shear, Neil H., Shieh, Christine, Straus, Sabine, Sukasem, Chonlaphat, Sung, Cynthia, Trubiano, Jason A., Tsou, Sheng-Ying, Ueta, Mayumi, Volpi, Simona, Wan, Chen, Wang, Hongsheng, Wang, Zhao-Qing, Weintraub, Jessica, Whale, Cindy, Wheatley, Lisa M., Whyte-Croasdaile, Sonia, Williams, Kristina B., Wright, Galen, Yeung, Sonia N., Zhou, Li, Chung, Wen-Hung, Phillips, Elizabeth J., and Carleton, Bruce C.
- Published
- 2021
- Full Text
- View/download PDF
8. Identification of novel Mycobacterium tuberculosis CD4 T-cell antigens via high throughput proteome screening.
- Author
-
Nayak, Kaustuv, Jing, Lichen, Russell, Ronnie M., Davies, D. Huw, Hermanson, Gary, Molina, Douglas M., Liang, Xiaowu, Sherman, David R., Kwok, William W., Yang, Junbao, Kenneth, John, Ahamed, Syed F., Chandele, Anmol, Murali-Krishna, Kaja, and Koelle, David M.
- Abstract
Summary Elicitation of CD4 IFN-gamma T cell responses to Mycobacterium tuberculosis (MTB) is a rational vaccine strategy to prevent clinical tuberculosis. Diagnosis of MTB infection is based on T-cell immune memory to MTB antigens. The MTB proteome contains over four thousand open reading frames (ORFs). We conducted a pilot antigen identification study using 164 MTB proteins and MTB-specific T-cells expanded in vitro from 12 persons with latent MTB infection. Enrichment of MTB-reactive T-cells from PBMC used cell sorting or an alternate system compatible with limited resources. MTB proteins were used as single antigens or combinatorial matrices in proliferation and cytokine secretion readouts. Overall, our study found that 44 MTB proteins were antigenic, including 27 not previously characterized as CD4 T-cell antigens. Antigen truncation, peptide, NTM homology, and HLA class II tetramer studies confirmed malate synthase G (encoded by gene Rv1837) as a CD4 T-cell antigen. This simple, scalable system has potential utility for the identification of candidate MTB vaccine and biomarker antigens. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Current status and prospects for development of an HSV vaccine.
- Author
-
Johnston, Christine, Koelle, David M., and Wald, Anna
- Subjects
- *
HERPES simplex virus , *VACCINE manufacturing , *VIRAL vaccines , *VIRUS diseases , *EPITOPES , *T cells , *GLYCOPROTEINS , *THERAPEUTICS - Abstract
Highlights: [•] HSV-2 is a highly prevalent infection that triples the risk of HIV-1 acquisition. [•] Prophylactic glycoprotein subunit vaccines have failed to decrease HSV-2 acquisition. [•] Identification of T-cell epitopes and new understanding of mucosal immunity have advanced vaccine development. [•] Re-evaluation of study population and endpoints for HSV vaccine trials is needed. [•] The HSV vaccine pipeline is rich with promising novel strategies in preclinical phase. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
10. T-cell immunity to human alphaherpesviruses.
- Author
-
Ouwendijk, Werner JD, Laing, Kerry J, Verjans, Georges MGM, and Koelle, David M
- Abstract
Highlights: [•] HSV T-cell immunity relies on multiple DC subsets and CD4/CD8 T-cell cooperation. [•] Diverse CD4/CD8 responses to HSV-1 are accessible with genome-spanning tools. [•] HSV-specific T-cells localize to mucosal epithelia during recurrent infections. [•] HSV-1-specific T-cells localize to ganglia during chronic latent infection. [•] VZV reactivation induces systemic and ganglionic T-cell responses. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
11. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons
- Author
-
Wald, Anna, Koelle, David M., Fife, Kenneth, Warren, Terri, LeClair, Kenneth, Chicz, Roman M., Monks, Stephen, Levey, Daniel L., Musselli, Cristina, and Srivastava, Pramod K.
- Subjects
- *
HERPES simplex virus , *PEPTIDES , *HIV-positive persons , *SENSORY ganglia , *DISEASE relapse , *T cells , *RECOMBINANT proteins , *GENITAL diseases - Abstract
Abstract: HSV-2, the primary causative agent of genital herpes, establishes latency in sensory ganglia and reactivates causing recurrent lesions and viral shedding. Induction or expansion of CD4+ and CD8+ T cell responses are expected to be important for a successful therapeutic vaccine against HSV-2. A candidate vaccine consisting of 32 synthetic 35mer HSV-2 peptides non-covalently complexed with recombinant human Hsc70 protein (named HerpV, formerly AG-707) was tested for safety and immunogenicity in a Phase I study. These peptides are derived from 22 HSV-2 proteins representative of all phases of viral replication. Thirty-five HSV-2 infected participants were randomized and treated in one of four groups: HerpV+QS-21 (saponin adjuvant), HerpV, QS-21, or vehicle. The vaccine was well tolerated and safe. All seven participants with evaluable samples who were administered HerpV with QS-21 demonstrated a statistically significant CD4+ T cell response to HSV-2 antigens, and the majority of such participants demonstrated a statistically significant CD8+ T cell response as well. To our knowledge, this is the first candidate vaccine against HSV-2 to demonstrate a broad CD4+ and CD8+ T cell response in HSV-2+ participants, and the first HSP-based vaccine to show immune responses against viral antigens in humans. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
12. Persistence of Herpes Simplex Virus Type 2 VP16-Specific CD4+ T Cells
- Author
-
Danke, Nancy A., Koelle, David M., and Kwok, William W.
- Subjects
- *
HERPES genitalis , *HERPES simplex virus , *HERPESVIRUS diseases , *LYMPHOCYTES - Abstract
Abstract: Patients with genital herpes have frequent viral reactivations. The repeated antigenic rechallenges can modulate the CD4+ memory T-cell repertoires during the course of infection. In this study, the CD4+ T-cell responses against the herpes simplex virus type 2 (HSV-2) tegument protein VP16 were studied in two HSV-2–infected subjects at two different time points that spanned a 5-year period. Although the VP16-specific T cells did exhibit variation of T-cell receptor Vβ usages at the two time points, T cells that used identical Vβ and CDR3 junction sequences were also observed at the two time points. These experiments demonstrate that the CD4+ T cells that are directed against HSV-2 VP16 protein in chronically infected individuals are oligoclonal and that T cells of specific clonotypes can be maintained throughout the course of the disease. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
13. Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results.
- Author
-
Redwood, Alec James, Rwandamuriye, Francois, Chopra, Abha, Leary, Shay, Ram, Ramesh, McDonnell, Wyatt, Konvinse, Katherine, White, Katie, Pavlos, Rebecca, Koelle, David M., Mallal, Simon, and Phillips, Elizabeth J.
- Published
- 2019
- Full Text
- View/download PDF
14. Patients with atopic dermatitis and history of eczema herpeticum elicit herpes simplex virus–specific type 2 immune responses.
- Author
-
Traidl, Stephan, Kienlin, Petra, Begemann, Gabriele, Jing, Lichen, Koelle, David M., Werfel, Thomas, and Roesner, Lennart M.
- Published
- 2018
- Full Text
- View/download PDF
15. A multifaceted high-throughput assay for probing antigen-specific antibody-mediated primary monocyte phagocytosis and downstream functions.
- Author
-
Zohar, Tomer, Atyeo, Caroline, Wolf, Caitlin R., Logue, Jennifer K., Shuey, Kiel, Franko, Nicholas, Choi, Robert Y., Wald, Anna, Koelle, David M., Chu, Helen Y., Lauffenburger, Douglas A., and Alter, Galit
- Subjects
- *
PHAGOCYTOSIS , *IMMUNE complexes , *HUMORAL immunity , *PHENOTYPIC plasticity , *MONOCLONAL antibodies - Abstract
Monocytes are highly versatile innate immune cells responsible for pathogen clearance, innate immune coordination, and induction of adaptive immunity. Monocytes can directly and indirectly integrate pathogen-destructive instructions and contribute to disease control via pathogen uptake, presentation, or the release of cytokines. Indirect pathogen-specific instructions are conferred via Fc-receptor signaling and triggered by antibody opsonized material. Given the tremendous variation in polyclonal humoral immunity, defining the specific antibody-responses able to arm monocytes most effectively remains incompletely understood. While monocyte cell line-based assays have been used previously, cell lines may not faithfully recapitulate the full biology of monocytes. Thus, here we describe a multifaceted antigen-specific method for probing antibody-dependent primary monocyte phagocytosis (ADMP) and secondary responses. The assay not only reliably captures phagocytic uptake of immune complexes, but also detects unique changes in surface markers and cytokine secretions profiles, poorly detected by monocytic cell lines. The assay captures divergent polyclonal-monocyte recruiting activity across subjects with varying SARS-CoV-2 disease severity and also revealed biological nuances in Fc-mutant monoclonal antibody activity related to differences in Fc-receptor binding. Thus, the ADMP assay is a flexible assay able to provide key insights into the role of humoral immunity in driving monocyte phenotypic transitions and downstream functions across many diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Stability of live attenuated rotavirus vaccine with selected preservatives and primary containers.
- Author
-
Lal, Manjari, Jarrahian, Courtney, Zhu, Changcheng, Hosken, Nancy A., McClurkan, Chris L., Koelle, David M., Saxon, Eugene, Roehrig, Andrew, Zehrung, Darin, and Chen, Dexiang
- Subjects
- *
GASTROENTERITIS in children , *ROTAVIRUS vaccines , *LOW-income countries , *ORAL medication , *DRUG delivery systems , *DOSE-effect relationship in pharmacology - Abstract
Rotavirus infection, which can be prevented by vaccination, is responsible for a high burden of acute gastroenteritis disease in children, especially in low-income countries. An appropriate formulation, packaging, and delivery device for oral rotavirus vaccine has the potential to reduce the manufacturing cost of the vaccine and the logistical impact associated with introduction of a new vaccine, simplify the vaccination procedure, and ensure that the vaccine is safely and accurately delivered to children. Single-dose prefilled presentations can be easy to use; however, they are typically more expensive, can be a bottleneck during production, and occupy a greater volume per dose vis-à-vis supply chain storage and medical waste disposal, which is a challenge in low-resource settings. Multi-dose presentations used thus far have other issues, including increased wastage of vaccine and the need for separate delivery devices. In this study, the goals were to evaluate both the technical feasibility of using preservatives to develop a liquid multi-dose formulation and the primary packaging alternatives for orally delivered, liquid rotavirus vaccines. The feasibility evaluation included evaluation of commonly used preservatives for compatibility with rotavirus vaccines and stability testing of rotavirus vaccine in various primary containers, including Lameplast's plastic tubes, BD's oral dispenser version of Uniject™ (Uniject DP), rommelag's blow-fill-seal containers, and MEDInstill's multi-dose vial and pouch. These presentations were compared to a standard glass vial. The results showed that none of the preservatives tested were compatible with a live attenuated rotavirus vaccine because they had a detrimental effect on the viability of the virus. In the presence of preservatives, vaccine virus titers declined to undetectable levels within 1 month. The vaccine formulation without preservatives maintained a stability profile over 12 months in all primary containers that was similar to its profile in standard glass vials. This study demonstrates that there are multiple options for the primary container for rotavirus vaccines intended for oral delivery. Selection of an optimal primary container should take into consideration additional factors, including stability as well as cold chain volume, usability, cost, and manufacturing feasibility. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
17. A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs.
- Author
-
Odegard, Jared M., Flynn, Patrick A., Campbell, David J., Robbins, Scott H., Dong, Lichun, Wang, Kening, ter Meulen, Jan, Cohen, Jeffrey I., and Koelle, David M.
- Subjects
- *
HERPES simplex vaccines , *VIRAL vaccines , *GLUCOPYRANOSE , *CD4 antigen , *CD8 antigen , *IMMUNITY - Abstract
Background/objectives There is currently no licensed prophylactic or therapeutic vaccine for HSV-2 infection. Methods We developed a novel preclinical vaccine candidate, G103, consisting of three recombinantly expressed HSV-2 proteins (gD and the UL19 and UL25 gene products) adjuvanted with the potent synthetic TLR4 agonist glucopyranosyl lipid A (GLA) formulated in stable emulsion. The vaccine was tested for immunogenicity and efficacy in pre-clinical models for preventative and therapeutic vaccination. Results Vaccination of mice with G103 elicited antigen-specific binding and neutralizing antibody responses, as well as robust CD4 and CD8 effector and memory T cells. The T cell responses were further boosted by subsequent challenge with live virus. Prophylactic immunization completely protected against lethal intravaginal HSV-2 infection in mice, with only transient replication of virus in the genital mucosa and sterilizing immunity in dorsal root ganglia. Supporting the use of G103 therapeutically, the vaccine expanded both CD4 and CD8 T cells induced in mice by previous infection with HSV-2. In the guinea pig model of recurrent HSV-2 infection, therapeutic immunization with G103 was approximately 50% effective in reducing the number of lesions per animal as well as the overall lesions score. Conclusions Taken together, the data show that G103 is a viable candidate for development of a novel prophylactic and therapeutic HSV-2 vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
18. Vascular E-Selectin Expression Correlates with CD8 Lymphocyte Infiltration and Improved Outcome in Merkel Cell Carcinoma.
- Author
-
Afanasiev, Olga K, Nagase, Kotaro, Simonson, William, Vandeven, Natalie, Blom, Astrid, Koelle, David M, Clark, Rachael, and Nghiem, Paul
- Subjects
- *
MERKEL cell carcinoma , *SKIN cancer , *LYMPHOCYTES , *T-cell lymphoma , *P-selectin glycoprotein ligand-1 , *BIOMARKERS - Abstract
Merkel cell carcinoma (MCC) is an aggressive, polyomavirus-linked skin cancer. Although CD8 lymphocyte infiltration into the tumor is strongly correlated with improved survival, these cells are absent or sparse in most MCCs. We investigated whether specific mechanisms of T-cell migration may be commonly disrupted in MCC tumors with poor CD8 lymphocyte infiltration. Intratumoral vascular E-selectin, critical for T-cell entry into skin, was downregulated in the majority (52%) of MCCs (n=56), and its loss was associated with poor intratumoral CD8 lymphocyte infiltration (P<0.05; n=45). Importantly, survival was improved in MCC patients whose tumors had higher vascular E-selectin expression (P<0.05). Local nitric oxide (NO) production is one mechanism of E-selectin downregulation and it can be tracked by quantifying nitrotyrosine, a stable biomarker of NO-induced reactive nitrogen species (RNS). Indeed, increasing levels of nitrotyrosine within MCC tumors were associated with low E-selectin expression (P<0.05; n=45) and decreased CD8 lymphocyte infiltration (P<0.05, n=45). These data suggest that one mechanism of immune evasion in MCC may be restriction of T-cell entry into the tumor. Existing therapeutic agents that modulate E-selectin expression and/or RNS generation may restore T-cell entry and could potentially synergize with other immune-stimulating therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
19. DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge
- Author
-
Kask, Angela Shaulov, Chen, Xianfeng, Marshak, Joshua O., Dong, Lichun, Saracino, Misty, Chen, Dexiang, Jarrahian, Courtney, Kendall, Mark A., and Koelle, David M.
- Subjects
- *
DNA vaccines , *HERPES simplex virus , *DOSE-effect relationship in pharmacology , *DRUG delivery systems , *INTRAMUSCULAR injections , *MICROPROJECTION , *IMMUNOGENETICS , *IMMUNE response - Abstract
Abstract: There is an unmet medical need for a prophylactic vaccine against herpes simplex virus (HSV). DNA vaccines and cutaneous vaccination have been tried for many applications, but few reports combine this vaccine composition and administration route. We compared DNA administration using the Nanopatch™, a solid microprojection device coated with vaccine comprised of thousands of short (110μm) densly-packed projections (70μm spacing), to standard intramuscular DNA vaccination in a mouse model of vaginal HSV-2 infection. A dose-response relationship was established for immunogenicity and survival in both vaccination routes. Appropriate doses administered by Nanopatch™ were highly immunogenic and enabled mouse survival. Vaginal HSV-2 DNA copy number day 1 post challenge correlated with survival, indicating that vaccine-elicited acquired immune responses can act quickly and locally. Solid, short, densely-packed arrays of microprojections applied to the skin are thus a promising route of administration for DNA vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
20. ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans
- Author
-
Jing, Lichen, McCaughey, Stella Mayo, Davies, D. Huw, Chong, Tiana M., Felgner, Phillip L., De Rosa, Stephen C., Wilson, Christopher B., and Koelle, David M.
- Subjects
- *
CELLULAR immunity , *CD4 antigen , *T cells , *VACCINIA , *MOLECULAR cloning , *HUMAN genome , *IMMUNOSPECIFICITY , *CYTOMETRY , *IMMUNOASSAY - Abstract
Abstract: The CD4 T-cell response to vaccinia promotes antibody and long-term CD8 responses. HLA class II molecules present microbial epitopes to CD4 T-cells. In humans, at least 3 loci encode cell-surface peptide-binding HLA class II heterodimers. Using intracellular cytokine cytometry (ICC) assays, we determined that HLA DR had the strongest contribution to vaccinia antigen presentation. Among panels of vaccinia-restricted T-cell clones, most were DR-restricted but rare DQ-restricted clones were also recovered. Vaccinia has over 200 open reading frames (ORFs), providing a significant bottleneck to assigning fine specificity. To overcome this, we expressed each predicted vaccinia ORF using in vitro transcription and translation. Array-based pool proteins were used to rapidly assign fine specificity to each DQ-restricted clone and to a sample of HLA DR-restricted clones. Reactivity was confirmed using synthetic peptides for selected CD4 T-cell clones. This method should be broadly applicable to the study of large-genome, sequenced pathogens, and could also be used to investigate T-cell responses to cDNAs expressed in neoplastic and autoimmune disorders in which CD4 responses might be adaptive or harmful. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.